# Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Source: https://onco.cc/trials/nct06596694/  
OnCo record `nct06596694` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Patritumab deruxtecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) is a phase 1/2 interventional study registered as NCT06596694 by Merck Sharp & Dohme LLC, with 180 participants planned, started 2024-11-03 and due to reach its primary completion in 2028-12-07. Interventions recorded: Patritumab deruxtecan.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06596694
- Phase: 1/2
- Setting: A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT06596694: https://clinicaltrials.gov/study/NCT06596694

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Patritumab deruxtecan](https://onco.cc/drugs/patritumab-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06596694.json